Combivent (ipratropium/salbutamol) / Boehringer Ingelheim - LARVOL DELTA

Unmasking Hypersensitivity Pneumonitis: A Complex Case of Environmental Exposures and COVID-19 (ATS 2025) - "He tested positive for COVID-19 at that time and was treated with benzonatate and Combivent...He was doing very well on clinic follow-up 1.5 weeks after finishing his prednisone taper. He continued to take fluticasone/salmeterol, which he believes helps...However, other differentials include interstitial lung disease secondary to adalimumab, COVID-19 pneumonitis, or possible asthma exacerbation. This case underscores the importance of surveying for environmental exposures in dyspneic patients especially when symptoms are persistent despite treatment. This also highlights that respiratory viral infections, and in this scenario, COVID-19, may contribute to the development of hypersensitivity pneumonitis."

Clinical • Asthma • Cough • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Interstitial Lung Disease • Novel Coronavirus Disease • Pain • Pneumonia • Pulmonary Disease • Ulcerative Colitis

Correct use of inhalers for asthma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A CASE OF INTRACTABLE WHEEZE IN A PATIENT WITH SEVERE ASTHMA DESPITE BIOLOGIC THERAPY (CHEST 2024) - "At the time of consultation, the patient was on fluticasone propionate/salmeterol 250/25 mcg two puffs twice daily, montelukast, tiotropium respimat, and Combivent scheduled four times daily. At that time, he was also on tezepelumab having received twelve months of treatment...He reported having five exacerbations in the last year requiring prednisone...IgE was 19 and peripheral eosinophils were as high as 0.4 x10^9/L before starting benralizumab... This case highlights the importance of recognizing ECAC as a potential confounder for patients with severe, uncontrolled asthma not responding to conventional therapy."

Clinical • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Comparison table: Inhaled drugs for treatment of COPD. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Drugs for COPD. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • Tobacco Cessation

Atomization efficacy of a novel micro-dose mesh nebulizer (CVS-100) versus the traditional mesh nebulizer (M102) in adults with chronic obstructive pulmonary disease: A randomized non-inferiority clinical trial. (PubMed, Respir Med) - "The novel micro-dose mesh nebulizer (CVS-100) was found to be non-inferior to the traditional mesh nebulizer (M102) in terms of the change in FEV1%pred from baseline after nebulization. Similar results were observed for all other measures of efficacy."

Head-to-Head • Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

"Eldepryl - combivent and soluble solpadeine" (@WalleyRay)

Differential Mechanisms of Dyspnea Relief in Advanced COPD: Opiates vs. Bronchodilators (clinicaltrials.gov) - P4 | N=20 | Completed | Sponsor: Queen's University | Suspended ➔ Completed | Trial completion date: Dec 2022 ➔ Mar 2023

Metastases • Trial completion • Trial completion date • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

"@FcoFdzClamont @salud_comision @SaludEdomex Gracias por surtir medicamentos. Aunque no dan tratamiento en @INSABI_mx @Juanferrer62 para asma/EPOC, al menos hay hoy me dieron un sustituto (Berodual) del Combivent @boehringerus ." (@laliz41)

"@INSABI_mx @Juanferrer62 @salud_comision @SSalud_mx @FcoFdzClamont Soy persistente cuando el tema amerita. No voy a dejar de escribirles J.Alcocer y Juan F. Ir a consulta de asma/epoc(grave),salir sin Combivent @boehringerus es absurdo. Es elmejor medicamento de rescate.Surtanlo!" (@laliz41)

Differential Mechanisms of Dyspnea Relief in Advanced COPD: Opiates vs. Bronchodilators (clinicaltrials.gov) - P4 | N=17 | Suspended | Sponsor: Queen's University | Trial completion date: Aug 2022 ➔ Dec 2022 | Trial primary completion date: Sep 2021 ➔ Sep 2022

Trial completion date • Trial primary completion date • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Effect of IFN-α and other commonly used nebulization drugs in different nebulization methods on the resistance of breathing circuit filters under invasive mechanical ventilation. (PubMed, Ann Transl Med) - "The remaining groups received jet nebulized or vibrating nebulized with either normal saline, Combivent, Amphotericin B, or IFN-α at a frequency of once every 12 hours separately and were removed from the breathing circuit after 24 hours...The effect of jet nebulization and vibrating mesh nebulization on the resistance of breathing filters showed no significant statistical difference. Jet nebulization with IFN-α significantly increased the resistance of the breathing filter within 24 hours and there was no significant difference in filter resistance between jet nebulization and vibrating mesh nebulization of IFN-α or Amphotericin B."

Journal • IFNA1

Differential Mechanisms of Dyspnea Relief in Advanced COPD: Opiates vs. Bronchodilators (clinicaltrials.gov) - P4; N=17; Suspended; Sponsor: Queen's University; Trial primary completion date: Mar 2021 ➔ Sep 2021

Trial primary completion date • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Drugs for asthma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Asthma • Immunology • Respiratory Diseases

Differential Mechanisms of Dyspnea Relief in Advanced COPD: Opiates vs. Bronchodilators (clinicaltrials.gov) - P4; N=17; Suspended; Sponsor: Queen's University; Trial primary completion date: Oct 2020 ➔ Mar 2021

Trial primary completion date • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Expanded table: Correct use of inhalers for asthma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Asthma • Immunology • Respiratory Diseases

"How come you no longer manufacture Combivent inhaler?" (@JaneVal45317286)

Drugs for COPD. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Chronic Obstructive Pulmonary Disease • Infectious Disease • Tobacco Cessation

Comparison table: Inhaled short-acting bronchodilators for treatment of COPD. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Chronic Obstructive Pulmonary Disease

Table: Correct Use of inhalers for COPD. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Asthma • Chronic Obstructive Pulmonary Disease • Respiratory Diseases

Differential Mechanisms of Dyspnea Relief in Advanced COPD: Opiates vs. Bronchodilators (clinicaltrials.gov) - P4; N=17; Suspended; Sponsor: Queen's University; Trial completion date: Aug 2020 ➔ Aug 2022; Recruiting ➔ Suspended; Trial primary completion date: Jun 2020 ➔ Oct 2020

Trial completion date • Trial primary completion date • Trial suspension • Chronic Obstructive Pulmonary Disease • Respiratory Diseases

Strategies to conserve salbutamol pressurized metered-dose inhaler stock levels amid COVID-19 drug shortage. (PubMed, Drugs Ther Perspect) - "Other short-acting muscarinic antagonists (SAMAs), such as ipratropium pMDI, and combinations of SABA/SAMA, such as Combivent Respimat, are also starting to have supply issues. These strategies include reprocessing used or expired pMDIs, using intravenous salbutamol and other short acting inhalers when available, and prescribing maintenance inhalers to prevent over usage of salbutamol pMDIs. We also highlight the important role of physicians and pharmacists in optimizing medication therapies to ensure adequate supplies."

Journal • Asthma • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

SACOPD: Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - P4; N=46; Completed; Sponsor: National Jewish Health; Active, not recruiting ➔ Completed

Trial completion • Biosimilar • Chronic Obstructive Pulmonary Disease • Immunology

Quantifying the importance of inhaler attributes corresponding to items in the patient satisfaction and preference questionnaire in patients using Combivent Respimat. (PubMed, Health Qual Life Outcomes) - "Most participants reported satisfaction with Combivent Respimat. Performance attributes were more important than convenience attributes."

Journal • Asthma • Biosimilar • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Coverage of combination regimens for COPD (AJMC) - "Byron Thomashow, MD: And having inhaler videos available within the app or a different portion, perhaps. Potentially getting pharmacists who work in CVS and Walgreens to show the person how to use the different devices. But we have to get away from this issue of somebody has changed their drug and they’re not using it."

Video